糖类抗原125和血清激肽释放酶10在上皮性卵巢癌中的表达

发布时间：2018-04-18 22:29

本文选题：上皮性卵巢癌 + 糖类抗原　；参考：《中国临床药理学杂志》2015年03期

【摘要】：目的探讨血清糖类抗原125(CA125)和激肽释放酶10(hk10)在上皮性卵巢癌中的表达及其在紫杉醇联合顺铂(TP)化疗方案疗效评估中的作用。方法 36例上皮性卵巢癌患者第1天24 h静脉滴注紫杉醇135 mg·m-2,第2,3天静脉滴注顺铂75 mg·m-2。酶联免疫吸附法(ELISA)检测36例上皮性卵巢癌患者及27例良性卵巢肿瘤患者血清CA125及hk10水平,分析2组患者CA125、hk10水平。同时检测28例卵巢癌患者TP化疗前后CA125和hk10水平变化及其与化疗疗效的相关性。结果卵巢癌组患者血清CA125及hk10水平显著高于良性卵巢肿瘤组(P均0.05)。28例卵巢癌患者接受TP方案化疗,完全缓解(CR)4例,部分缓解(PR)11例,稳定(SD)3例,进展(PD)10例,客观缓解率为64.3%。CR组化疗后CA125及hk10水平显著低于SD及PD组(P0.05)。结论卵巢癌患者血清CA125和hk10水平显著升高,可以作为TP方案化疗疗效的评估指标。
[Abstract]:Objective to investigate the expression of serum carbohydrate antigen 125 (CA125) and kallikrein 10hk10) in epithelial ovarian cancer and its role in evaluating the efficacy of paclitaxel combined with cisplatin (TPTP) regimen.Methods Thirty-six patients with epithelial ovarian cancer were treated with paclitaxel 135mg m ~ (-2) and cisplatin 75 mg m ~ (-2) on day 2 and day 3 respectively.Serum CA125 and hk10 levels were measured by Elisa in 36 patients with epithelial ovarian cancer and 27 patients with benign ovarian tumor, and CA125hk10 levels were analyzed in both groups.The changes of CA125 and hk10 in 28 patients with ovarian cancer before and after TP chemotherapy were also detected.Results the serum levels of CA125 and hk10 in ovarian cancer group were significantly higher than those in benign ovarian tumor group (P 0.05). 28 cases of ovarian cancer received TP regimen chemotherapy, 4 cases of complete remission, 11 cases of partial remission, 3 cases of stable SDN and 10 cases of progression.The objective remission rate was that the levels of CA125 and hk10 in 64.3%.CR group were significantly lower than those in SD and PD groups after chemotherapy (P 0.05).Conclusion the serum levels of CA125 and hk10 in patients with ovarian cancer are significantly increased, which can be used as an index to evaluate the efficacy of TP regimen chemotherapy.
【作者单位】：福建医科大学附属第一医院妇产科;长沙市妇幼保健院妇产科;
【基金】：福建省科教育厅基金资助项目(JA12145)
【分类号】：R737.31

【参考文献】